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Abstract
Background
Identification of families at risk for ovarian cancer offers the opportunity to consider prophy-
lactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially
affected families in Germany was solely performed via family history and numbers of
affected family members with breast or ovarian cancer. However, neither the prevalence of
deleterious variants in BRCA1/2 in ovarian cancer in Germany nor the reliability of family his-
tory as trigger for genetic counselling has ever been evaluated.
Methods
Prospective counseling and germline testing of consecutive patients with primary diagnosis
or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included
25 candidate and established risk genes. Among these 25 genes, 16 genes (ATM, BRCA1,
BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PMS2, PTEN, PALB2, RAD51C,
RAD51D, STK11, TP53) were defined as established cancer risk genes. A positive family
history was defined as at least one relative with breast cancer or ovarian cancer or breast
cancer in personal history.
Results
In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer
and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years
(range 16–93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total,
27.9% of the patients showed at least one deleterious variant in all 25 investigated genes
and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the
BRCA1 (15.5%), BRCA2 (5.5%), RAD51C (2.5%) and PALB2 (1.1%) genes. The preva-
lence of deleterious variants did not differ significantly between patients at primary diagnosis
and relapse. The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in
patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients60 years. Family
history was positive in 43% of all patients. Patients with a positive family history had a preva-
lence of deleterious variants of 31.6% (36.0%) versus 11.4% (17.6%) and histologic subtype
of high grade serous ovarian cancer versus other showed a prevalence of deleterious vari-
ants of 23.2% (29.1%) and 10.2% (14.8%), respectively. Testing only for BRCA1/2 would
miss in our series more than 5% of the patients with a deleterious variant in established risk
genes.
Conclusions
26.4% of all patients harbor at least one deleterious variant in established risk genes. The
threshold of 10% mutation rate which is accepted for reimbursement by health care provid-
ers in Germany was observed in all subgroups analyzed and neither age at primary diagno-
sis nor histo-type or family history sufficiently enough could identify a subgroup not eligible
for genetic counselling and testing. Genetic testing should therefore be offered to every
patient with invasive epithelial ovarian cancer and limiting testing to BRCA1/2 seems to be
not sufficient.
Genetic risk of ovarian cancer patients
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Introduction
Ovarian cancer is the leading cause of death of all gynecologic cancers both in the European
Union and the United States [1]. In the US, 22,280 patients were diagnosed in 2016 for ovarian
cancer and 14,240 died [2]. Despite improvements in chemotherapy [3,4,5] and surgery [6,7]
still most patients relapse and finally die of disease. A decade ago, it was estimated that about
10–15% of all patients have a hereditary risk for ovarian cancer [8,9]. The first identified pre-
disposition genes were BRCA1 and BRCA2with a lifetime penetrance regarding ovarian cancer
of 35–59% (BRCA1) and 11–17% (BRCA2), respectively [10,11,12,13]. Unfortunately, several
trials which tried to establish a successful screening for ovarian cancer failed [14]. The develop-
ment of a serous tubal intraepithelial carcinoma (STIC) as a precursor lesion in the fallopian
tube with the potential to metastasize within the peritoneal cavity before a solid tumor in the
pelvis can be detected, might be one reason for the trial failures [15,16]. Consequently, the
majority of patients is diagnosed at an advanced stage with the above-mentioned mortality. So
far, the only effective method to reduce the mortality is risk-reducing surgery including bilat-
eral salpingo-oophorectomy (rrBSO) [17]. As rrBSO cannot be recommend to the general
population, identification of population at risk might help to identify those women in whom
the benefit of rrBSO may outweight it’s burden. Identifying families with deleterious BRCA1/2
variants might provide this opportunity.
So far, we did not know how many family members must be affected before we can assume
an elevated risk for their relatives and especially, if one affected member already qualifies for
genetic testing. A further hurdle is the decreasing number of family members in Germany
over decades and more recently the increase of so-called blended families. In Germany and in
most other countries, genetic testing of patients with ovarian cancer is limited to patients with
a family history of breast and/or ovarian cancer. The aim of this study was to investigate the
prevalence of genetic risk factors in consecutive patients with ovarian cancer irrespective of
family history and histologic subtype treated in centers of the Arbeitsgemeinschaft Gyna¨kolo-
gische Onkologie (AGO) study group. In addition, we wanted to evaluate patient satisfaction
with gynecological oncology counseling.
Methods
Patients
The protocol was approved by the ethical committee of the Landesaerztekammer Nordrhein
(Nr. 2014340) and registered (NCT02222883); all patients gave written informed consent
prior to any study related procedure. Patients aged at least 18 years with primary diagnosis
or platinum-sensitive relapse of invasive epithelial ovarian cancer in Germany were tested
and counselled in 20 centers of the AGO study group in Germany. Platinum sensitive disease
was defined as relapse at least 6 months after prior platinum based chemotherapy. It was
allowed to include patients up to 6 months after last platinum dose and patients with more
than one prior platinum line. We excluded patients with non-epithelial ovarian malignancy
and those with a platinum-free interval of less than 6 months. Demographic data, disease
characteristics, family history, and medical history were documented. Further follow up of
the patients is planned for 5 years and will be reported later. A positive family history was
defined as at least one relative with breast cancer or ovarian cancer or breast cancer in per-
sonal history. This means, that also patients with the diagnosis of breast cancer in personal
history and now the additional diagnosis of ovarian cancer were classified as having a posi-
tive family history.
Genetic risk of ovarian cancer patients
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Gene selection
Germline testing was centrally performed at the Center of Hereditary Breast and Ovarian Can-
cer at the University of Cologne, Germany. Testing included 25 established and candidate risk
genes related to ovarian and/or breast cancer or rare cancer predisposition syndromes (ATM,
BARD1, BRCA1, BRCA2, BRIP1, BUB1B, CDH1, CHEK1,CHEK2, FAM175A, FANCM, MLH1,
MSH2, MSH6, MRE11A,NBN, PMS2, PTEN, PALB2, RAD50,RAD51C,RAD51D, STK11,
TP53, XRCC2). Among these 25 genes, 16 were defined as as established cancer “risk genes”,
including the Lynch syndrome-associated genes (MLH1, MSH2, MSH6, PMS2), genes causa-
tive for rare cancer predisposition syndromes (CDH1, PTEN, STK11, TP53), and genes known
to contribute to hereditary breast and/or ovarian cancer risk, namely ATM, BRCA1, BRCA2,
CHEK2,NBN, PALB2, RAD51C and RAD51D [18,19,20,21,22]. For the remaining 9 genes,
only limited evidence is available so far for BUB1B, BARD1, BRIP1, CHEK1, FANCM,
FAM175A, MRE11A,RAD50 and XRCC2 [23,24,25,26,27,28]. BUB1B and CHEK1were
included because deleterious variants in both genes have been described in ovarian cancer
patients [29]. We classified the analyzed genes in 3 different categories: BRCA1/BRCA2 (group
A), 16 risk genes (group B) and all 25 genes (group C).
Genetic analyses
Genomic DNA was isolated from venous blood samples using standard methods. All samples
were screened for gross genomic aberrations in the BRCA1/2 genes by Multiplex Ligation-
dependent Probe Amplification (MLPA) using the SALSA1 MLPA1 probemixes P002
(BRCA1) and P045 (BRCA2) (MRC-Holland, Amsterdam, The Netherlands) according to the
manufacturers protocol. Data was analysed using the Coffalyzer.Net v.140429.1057 software
(MRC-Holland). All BRCA1/2 deletions/duplications were verified using the SALSA1
MLPA1 probemixes P087 (BRCA1) or P077 (BRCA2), respectively (MRC-Holland). All sam-
ples were subsequently analyzed by next generation sequencing (NGS) covering the entire cod-
ing regions and exon-flanking sequences (±15nt) of the 25 above-mentioned genes. For NGS,
we employed a customer-tailored SureSelect gene panel (Agilent, Santa Clare, U.S.) using the
XT Target Enrichment for Illumina Paired-End Multiplexed Sequencing protocol optimized
for 200ng of genomic DNA (Agilent). Sequencing was performed on MiSeq or HiSeq4000
devices (Illumina, San Diego, U.S.). Bioinformatic analyses were carried out using the VAR-
BANK version 2.10 pipeline of the Cologne Center for Genomics. In addition, the obtained
NGS data were utilized to identify LGRs (large genomic rearrangements) in non BRCA1/2
genes using an in silico CNV-Tool incorporated in the Sophia DDM1 platform (Sophia
Genetics). Conspicuous regions indicative for a duplication or deletion were verified using an
appropriate SALSA1 MLPA1 probemix, if available (MRC-Holland) or by aCGH (Array
comparative genomic hybridization) using a customized probe set covering the regions of
interest (Agilent).
Variant classification
Variant classification was performed in accordance with the regulations of the international
ENIGMA consortium (Evidence-based Network for the Interpretation of Germline Mutant
Alleles; https://enigmaconsortium.org; version 1.1: 26th of March 2015). All genetic variants
were classified using a 5-tier variant classification system as proposed by the International
Agency for Research on Cancer (IARC) Unclassified Genetic Variants Working Group,
namely, deleterious = class 5, likely deleterious = class 4, variant of uncertain significance
(VUS) = class 3, likely benign = class 2, and benign = class 1 [30]. Variants reported to occur
in large outbred control reference groups at an allele frequency1% (MAF 0.01) are
Genetic risk of ovarian cancer patients
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generally considered to be benign (class 1). Class 4/5 variants are subsequently denominated
as ´deleterious variants´. All deleterious variants were validated by Sanger sequencing.
Counselling
Counselling was performed by gynecologic oncologists according to local standard and we eval-
uated the patient perspectives and satisfaction regarding testing and counseling by a survey.
Patients had a BRCA elucidation before testing by their treating gynecologic oncologist and in
case of a positive result a subsequent counselling by a gynecologic oncologist or geneticist
depending on the local standard. The patients were asked the following questions after testing:
• Finden Sie es gut, dass Ihnen eine Beratung und Testung bzgl. ihres familia¨ren Risikos ange-
boten wurde? (Did you appreciate that counselling and testing regarding your family risk
was offered to you?)
• Waren Sie mit der Beratung zufrieden? (Were you satisfied with the counselling?)
• Waren Sie mit der Ergebnismitteilung zufrieden? (Were you satisfied with how the result
was communicated?)
Statistical methods
The protocol stated a target sample size of 500 patients. No formal power analysis was per-
formed. The primary objectives were to assess the prevalence of deleterious germline variants
in the investigated genes. All analyses are merely descriptive; no confirmatory hypothesis test-
ing was done. The prevalence was calculated as number of patients with at least one deleterious
variant in the respective genes or gene categories divided by all tested patients. SAS version 9.4
was used for all statistical analyses. Further details are provided in the study protocol (S1 study
protocol and S1 Trend Statement Checklist)
Results
In total, 525 patients were registered and blood was sent for testing in 523 cases including 281
patients with primary ovarian cancer and 242 with relapsed platinum-sensitive ovarian cancer
between 3/2015 and 7/2015 (Table 1). The majority of the patients were of White/Caucasian/
Table 1. Patient characteristics.
Variable All (n = 523)
Age (mean, range) [years] 58 (16–93)
Positive family history (%) 225 (43.0)
Histologic subtype (%)
High grade serous 406 (77.6)
High grade endometrioid 23 (4.4)
Low grade serous 18 (3.4)
Low grade endometrioid 7 (1.3)





Primary ovarian cancer 281 (53.7)
Recurrent ovarian cancer 242 (46.3)
https://doi.org/10.1371/journal.pone.0186043.t001
Genetic risk of ovarian cancer patients
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European heritage (96.8%) followed by White/Arabic/North African heritage with 1.3%. Other
ethnicities were more infrequent (< 0.5%). The mean age at primary diagnosis of all patients
was 58 years, 43% had a positive family history and 77.6% showed a high-grade serous ovarian
cancer (Table 1). In total, 146 of 523 patients (27.9%) showed a deleterious variant in at least
one of the investigated genes (S1 Table), of which 9 patients carried two deleterious germline
variants (S2 Table). In the overall sample, 109 patients carried a deleterious variant in BRCA1,
BRCA2, or both genes (Table 2, S1 and S2 Tables). In this subgroub of 109 patients with delete-
rious BRCA1/2 variants, 6 carried deleterious variants in further genes investigated in this
study (Table 2). Deleterious germline variants in BRCA1 were most abundant (81 patients,
15.5%), followed by BRCA2 (29 patients, 5.5%), RAD51C (13 patients, 2.5%) and PALB2 (6
patients, 1.1%). Deleterious variants in all other genes analyzed were identified in less than 1%
of the patients each (Table 2). The combined analysis showed the following prevalence of dele-
terious veriants for the respective categories: BRCA1/2: 20.8% (group A, 109 patients); risk
genes: 26.4% (group B, 138 patients); all genes: 27.9% (group C, 146 patients). The number of
Table 2. Prevalence of deleterious variants in the selected genes. No deleterious variants were
observed in BARD1, CDH1, MLH1, PMS2, PTEN, STK11 and TP53.
Genes / gene categories Patients, (% of all; n = 523)
BRCA1/2 (group A) 109 (20.8)
risk genes (group B) 138 (26.4)
any gene (group C) 146 (27.9)
Group A (109 patients)
BRCA1 only 78 (15.0)
BRCA1 and NBN 1 (0.2)
BRCA1 and XRCC2 1 (0.2)
BRCA1 and BRCA2 1 (0.2)
BRCA2 only 24 (4.6)
BRCA2 and FANCM 2 (0.4)
BRCA2 and RAD50 1 (0.2)
BRCA2 and BUB1B 1 (0.2)
Group B (138 patients)
BRCA1/2 carriers 109 (20.8)
RAD51C only 13 (2.5)
PALB2 only 5 (1.0)
PALB2 and ATM 1 (0.2)
ATM only 1 (0.2)
RAD51D only 3 (0.6)
MSH2 only 2 (0.4)
CHEK2 and BRIP1 1 (0.2)
CHEK2 only 1 (0.2)
NBN only 1 (0.2)
MSH6 only 1 (0.2)
Group C (146 patients)
risk genes (group B) 138 (25.8)
FANCM only 3 (0.6)
MRE11A only 2 (0.4)
CHEK1 only 1 (0.2)
FAM175A only 1 (0.2)
BRIP1 only 1 (0.2)
https://doi.org/10.1371/journal.pone.0186043.t002
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patients with at least one deleterious vatiant in any gene (group C) was slightly though not sta-
tistically significantly higher in the relapsed versus the primary diagnosis cohort (21.4% [76 of
242] versus 24.9% [70 of 281]; two-sided chi-square p = 0.1).
Furthermore, we analyzed the prevalence of deleterious variants by different subgroups
regarding age (< versus 60 years), family history (positive versus negative) and histologic
subtypes (high-grade serous versus others). All analyses in all subgroups showed a prevalence
of deleterious BRCA1/2 variants above 10.0%. The highest prevalence of deleterious BRCA1/2
variants was 30.2% in patients below the age of 60 years at primary diagnosis and 31.6% with a
positive family history, respectively. Of note, 33/109 patients (30.3%) with deleterious BRCA1/
2 variants would have been missed by using the classical criteria family history. This rate
increases to missing 51/138 patients (37%) regarding the 16 risk genes as defined in our series.
However, the threshold frequency of 10% that qualifies for reimbursement of consultation and
testing was observed in every subgroup analyzed and even analysis per decade of patients’ age
did not identify any subgroup with a lower rate of deleterious variants—unfortunately, we
were not able to analyze patients in their octogenarium who are underrepresented in our trial
with 11 patients only.
The prevalence of deleterious variants in the 16 risk genes ranged from 14.8% (patients
with a histologic subtype other than HGS, Table 3) to 36.0% (patients with a positive family
history, Table 3) and the prevalence of deleterious variants in any of the investigated genes
from 16.7 (patients with a histologic subtype other than HGS, Table 3) to 36.4% (patients with
a positive family history, Table 3). The number of patients with non high-grade serous histo-
logic subtypes was limited, however, deleterious BRCA1/2 variants were also detected in non
high grade serous histo-types. Twenty-three patients had high-grade endometrioid histology.
This subtype showed a prevalence of deleterious variants in the BRCA1/2 genes of 13%, 21.7%
had a deleterious variant in at least one of the 16 risk genes. Furthermore, we had 18 patients
with low-grade serous histology (deleterious variant in BRCA1/2: 5.6%, risk gene: 11.1%, any
gene: 16.7%). All other known histologic subtypes included less than 10 patients (Table 4). The
rate of deleterious variants in the Lynch-associated genes (MSH2, MSH6, MLH1, PMS2) was
0.6% (3 patients; 2 MSH2-positive patients, 1 with high grade serous and 1 with high-grade
endometrial subtype; 1 MSH6-positive patient with high-grade serous subtype).
Table 3. Prevalence of deleterious variants within subgroups.






All (%) 523 109 (20.8) 138 (26.4) 146 (27.9)
Age*
< 60 years 268 81 (30.2) 89 (33.2) 94 (35.1)
 60 years 254 27 (10.6) 48 (18.9) 51 (20.1)
Family history
Positive 225 71 (31.6) 81 (36.0) 82 (36.4)
Negative 289 33 (11.4) 51 (17.6) 58 (20.1)
Histologic subtype*
High grade serous (HGS) 406 94 (23.2) 118 (29.1) 123 (30.3)
other 108 11 (10.2) 16 (14.8) 18 (16.7)
Within subset of HGS
Primary diagnosis 203 46 (22.7) 54 (26.6) 57 (28.1)
Relapse 203 48 (23.6) 64 (31.5) 66 (32.5)
* Age class was missing for 1 patient; histologic subtype was missing for 9 patients.
https://doi.org/10.1371/journal.pone.0186043.t003
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The compliance with the survey was high and the rate of responders for each of the ques-
tions was 80.9% each (“Did you appreciate that counselling and testing regarding your family
risk was offered to you?” and “Were you satisfied with the counselling?”) and 66.2% (“Were
you satisfied with how the result was communicated?”). Question 1 (Did you appreciate that
counselling and testing regarding your family risk was offered to you?) was answered with
“yes” by 98.4%, question 2 (Were you satisfied with the counselling?) by 93.9% and question 3
(Were you satisfied with how the result was communicated?) by 97.4% of the participating
patients. The corresponding rates for “No” were 0.5%, 3.2%, and 1.2%, respectively. The rates
of “I don’t know” were 1.2%, 2.9% and 1.2%, respectively.
Discussion
Our data indicate that a genetic background regarding the development of ovarian cancer is
present in a higher proportion of patients than anticipated in the past. The strength of our trial
is the testing of consecutive unselected patients with ovarian cancer in a multicenter setting.
The rate of patients with deleterious variants in BRCA1/2was about 21% without any mean-
ingful difference between patients with first diagnosis or relapsed disease. This is in line with
other recent publications reporting a rate of BRCA1/2 carriers of about 16–19% [23, 31,32].
One of the main questions for the future is therefore, how we could prevent about 1/5 of all
ovarian cancer cases. According to the National Institute for Health and Care Excellence
(NICE), genetic BRCA1/2 testing is generally recommended when the combined probability to
detect a deleterious BRCA1 and BRCA2 variant is 10% [27]. Thus, age at onset and family
history were the main selection criteria to identify suitable index patients for genetic testing to
identify families at risk. However, this resulted in multiple different guidelines regarding selec-
tion criteria differing between the countries and medical societies [33]. Family history and age
at onset are only of limited value to identify patients at genetic risk. This was already reported
by other authors [34,35,36,37,38]. Using traditional criteria might miss about one third of all
patients with a hereditary risk regarding BRCA1/2. In our cohort, 33/109 patients (30.28%)
with deleterious variants in BRCA1/2would have been missed by using only classical criteria
like family history. This rate increases to missing 51/138 patients (37%) regarding the 16 risk
genes as defined in our series. Disease modifiers that are independent from BRCA1/2, de novo
mutations, or limited family structures may explain the finding that a subgroup of BRCA1/2-
positive patients with ovarian cancer did not show a positive family history.
A limitation of our series is the limited number of patients with other histologic subtypes
than high-grade serous ovarian cancer. Unfortunately, we have only less than 10 patients with
a mucinous or clear cell histologic subtype. Therefore, we are not able to give an appropriate
answer regarding the rate of deleterious variants in this subtype. Of note, we reported already
the finding of deleterious BRCA1/2 variants in patients with clear cell and mucinous ovarian
cancer within an international multicenter first line therapy trial [31]. Whether this finding
Table 4. Histologic subtypes and prevalence of deleterious variants in patients with serous, endometrioid, mucinous or clear cell ovarian cancer.






High grade serous 406 94 (23.2) 118 (29.1) 123 (30.3)
Low grade serous 18 1 (5.6) 2 (11.1) 3 (16.7)
High grade endometrioid 23 3 (13.0) 5 (21.7) 5 (21.7)
Low grade endometrioid 7 1 (14.3) 1 (14.3) 1 (14.3)
Mucinous 9 0 0 1 (11.11)
Clear cell 6 0 0 0
https://doi.org/10.1371/journal.pone.0186043.t004
Genetic risk of ovarian cancer patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0186043 October 20, 2017 8 / 12
was by chance or revealed indeed the driver alterations for ovarian cancers remains an open
question. In addition, the changed classification of the histologic subtypes in ovarian cancer in
2014 has to be kept in mind as further potential factor. Within a large multicenter study, it was
shown that reviewing the pathologic samples by an expert gynecologic pathologist using the
old and new classification system results in diagnosing the same histologic subtype again in
only 54% [39]. In accordance to another recent presentation, we could also show that gyneco-
logic oncologist led testing shows a high level of satisfaction in patients with ovarian cancer
[40].
In conclusion, the limited value of any supporting instruments to identify families at risk of
ovarian cancer highlights the necessity to offer germline testing to all patients with ovarian
cancer. This is so far the only option we have, to identify families at risk for the usually fatal
course of the disease of ovarian cancer. Offering prophylactic surgery in BRCA1/2-positive
women is the only effective option to decrease ovarian cancer mortality. Therefore, Scotland
established offering genetic testing to all patients with non-mucinous histologies of ovarian
cancer already in 2013 [41]. The results of our study were already discussed with German
health care providers and the Medizinische Dienst der Krankenkassen (MDK), which led to
offering testing to all patients with ovarian cancer up to the age of 80 years who were covered
by the Verband der Ersatzkassen in Germany in October 2016. Negotiations with further
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